GEN-PROBE(R) AMPLIFIED(TM) MYCOBACTERIUM TUBERCULOSIS DIRECT (MTD) TEST

FDA Premarket Approval P940034 S008

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

This device, a target-amplified nucleic acid probe test, is indicated for: the in vitro diagnostic detection of mycobacterium tuberculosis complex rrna in acid-fast bacilli (afb) smear positive and negative concentrated sediments prepared from sputum (induced or expectorated), bronchial specimens (e. G. , bronchalveolar lavages or bronchial aspirates) or tracheal aspirates. The mtd test is intended for use only with specimens from patients showing signs and symptoms consistent with active pulmonary tuberculosis. Mtd is to be used as an adjunctive test for evaluating either afb smear positive or negative sediments prepared using nalc-naoh digestion-decontamination of respiratory specimens. Patients who are suspected of having pulmonary tb based on clinical evaluation and who have received no antituberculous therapy, less than 7 days of such therapy, or have not received such therapy in the last 12 months may be evaluated with this test. The mtd test should be performed only in laboratories proficient in the culture and identification of m. Tuberculosis (level ii and iii or extent 3 and 4). The mtd test must be performed in conjunction with mycobacterial culture.

DeviceGEN-PROBE(R) AMPLIFIED(TM) MYCOBACTERIUM TUBERCULOSIS DIRECT (MTD) TEST
ApplicantGEN-PROBE, INC.
Date Received1998-09-04
Decision Date1999-09-30
Notice Date2000-02-15
PMAP940034
SupplementS008
Docket Number00M-0578
Advisory CommitteeMicrobiology
Supplement TypePanel Track
Supplement ReasonLabeling Change - Indications/instructions/shelf Life/tradename
Expedited ReviewNo
Combination Product No
Applicant Address GEN-PROBE, INC. 10210 Genetic Center Dr. san Diego, CA 92121
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P940034Original Filing
S019 2012-11-07 30-day Notice
S018 2010-03-31 30-day Notice
S017 2006-07-27 135 Review Track For 30-day Notice
S016 2004-09-21 30-day Notice
S015 2004-01-22 30-day Notice
S014
S013 2001-12-18 Special (immediate Track)
S012 2001-03-02 Normal 180 Day Track
S011 2000-10-25 Real-time Process
S010 1999-05-12 30-day Notice
S009 1998-10-19 Special (immediate Track)
S008 1998-09-04 Panel Track
S007 1998-08-17 Normal 180 Day Track
S006 1997-09-15 Normal 180 Day Track
S005 1997-07-02 Normal 180 Day Track
S004 1997-01-24 Normal 180 Day Track
S003 1996-06-17 Normal 180 Day Track
S002 1996-05-22 Special (immediate Track)
S001 1996-02-23 Normal 180 Day Track

NIH GUDID Devices

Device IDPMASupp
15420045500303 P940034 019

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.